Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Obalon Therapeutics Inc (OBLN)

Obalon Therapeutics Inc (OBLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,418
  • Shares Outstanding, K 5,573
  • Annual Sales, $ 9,100 K
  • Annual Income, $ -37,380 K
  • 60-Month Beta -4.87
  • Price/Sales 1.01
  • Price/Cash Flow N/A
  • Price/Book 0.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.50
  • Number of Estimates 1
  • High Estimate -1.50
  • Low Estimate -1.50
  • Prior Year -3.90
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.52 +9.87%
on 11/11/19
2.22 -24.77%
on 10/22/19
-0.01 (-0.60%)
since 10/11/19
3-Month
1.52 +9.87%
on 11/11/19
2.75 -39.27%
on 08/14/19
-1.02 (-37.92%)
since 08/13/19
52-Week
1.52 +9.87%
on 11/11/19
34.00 -95.09%
on 12/21/18
-18.83 (-91.85%)
since 11/13/18

Most Recent Stories

More News
OBALON THERPTCS (OBLN) Reports Q3 Loss, Misses Revenue Estimates

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 82.57% and -84.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

OBLN : 1.67 (-1.18%)
Obalon Announces Third Quarter 2019 Financial Results

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced...

OBLN : 1.67 (-1.18%)
Obalon Announces Clinical Data Set to be Featured During the 36th ASMBS Annual Meeting at Obesity Week 2019

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces...

OBLN : 1.67 (-1.18%)
OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OBLN : 1.67 (-1.18%)
Obalon Schedules Third Quarter 2019 Financial Results Conference Call for November 8, 2019 at 9:00 a.m. Eastern Time

Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces...

OBLN : 1.67 (-1.18%)
Will OBALON THERPTCS (OBLN) Report Negative Q3 Earnings? What You Should Know

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OBLN : 1.67 (-1.18%)
Obalon Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric...

OBLN : 1.67 (-1.18%)
Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has...

OBLN : 1.67 (-1.18%)
Obalon Announces Repayment of All Long-Term Debt and Regaining of Compliance with NASDAQ Listing Requirement

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for...

OBLN : 1.67 (-1.18%)
Obalon (OBLN) Alert: Johnson Fistel Announces Shareholder Class Action Against Obalon Therapeutics Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?

Johnson Fistel, LLP is investigating potential claims on behalf of Obalon Therapeutics, Inc. (NASDAQ: OBLN) ("Obalon" or the "Company") against certain of its officers and directors.

OBLN : 1.67 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade OBLN with:

Business Summary

Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained...

See More

Key Turning Points

2nd Resistance Point 1.74
1st Resistance Point 1.71
Last Price 1.67
1st Support Level 1.63
2nd Support Level 1.58

See More

52-Week High 34.00
Fibonacci 61.8% 21.59
Fibonacci 50% 17.76
Fibonacci 38.2% 13.93
Last Price 1.67
52-Week Low 1.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar